NCT05162469View on ClinicalTrials.gov

A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 23, 2022

Primary Completion Date

March 28, 2024

Study Completion Date

June 13, 2024

Conditions
Advanced Malignant Cancer
Interventions
DRUG

SHR-1909 injection

SHR-1909 for intravenous injection;Strength:6ml:0.3g/vial. Dose escalation (non randomized, 6 dose-levels); Dose-expansion and efficacy-expansion(non-randomized,1-3 dose-level(s)).

Trial Locations (1)

130000

Jilin Cancer Hospital, Changchun

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY